Ads
related to: does rituximab affect plasma cells treatment mayo clinicinfo.biolifeplasma.com has been visited by 10K+ users in the past month
vyvgarthcp.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
In hematology, plasma cell dyscrasias (also termed plasma cell disorders and plasma cell proliferative diseases) are a spectrum of progressively more severe monoclonal gammopathies in which a clone or multiple clones of pre-malignant or malignant plasma cells (sometimes in association with lymphoplasmacytoid cells or B lymphocytes) over-produce and secrete into the blood stream a myeloma ...
Otherwise, treatment is divided based on the local versus systemic spread of its clonal plasma cells. Patients with one or two plasmacytoma bone lesions and no clonal plasma cells in their bone marrow biopsy specimens are treated by surgical removal or radiotherapy of their tumors. These treatments can relieve many of the syndromes clinical ...
CD20 is a protein that is found on the surface of B-cells and thus serves as an important target in the treatment of many B-cell malignances, including CLL. [45] Some CD20 antibodies that have been used for the treatment of CLL include: [45] Rituximab; Ofatumumab; Obinutuzumab
Robert A. Kyle is a professor of medicine, Laboratory Medicine and Pathology at the Mayo Clinic.He specializes in the care of patients with plasma cell dyscrasias. . Throughout his career Kyle has published more than 1,850 scientific papers and abstracts on myeloma and other plasma cell diso
The common non-Hodgkin treatment, rituximab (which is a monoclonal antibody against CD20) is not routinely used to treat Hodgkin lymphoma due to the lack of CD20 surface antigens in most cases. The use of rituximab in Hodgkin lymphoma, including the lymphocyte predominant subtype has been recently reviewed. [49]
Ads
related to: does rituximab affect plasma cells treatment mayo clinicinfo.biolifeplasma.com has been visited by 10K+ users in the past month